Peritoneal Metastases Clinical Trial
Official title:
Feasibility of the LUM Imaging System for Detection of Peritoneal Surface Malignancies
The objective of this feasibility study is to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and mesothelioma. This feasibility study consists of two parts: (a) a dose escalation phase to select the optimal dose followed by (b) enrollment of additional patients to develop the tumor detection algorithm.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 1, 2026 |
Est. primary completion date | December 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must have histologically or cytologically confirmed metastases to the peritoneum from gastrointestinal cancer, ovarian cancer or mesothelioma prior to surgery. - Subjects must be scheduled for surgical resection. - Age of 18 years or older. - Subjects must be able and willing to follow study procedures and instructions. - Subjects must have received and signed an informed consent form. - Subjects must be otherwise healthy except for the diagnosis of cancer, as per the criteria listed below. - Subjects must have normal organ and marrow function as defined as: - Leukocytes > 3,000/mcL - Absolute neutrophil count > 1,500/mcL - Platelets > 100,000/mcL - total bilirubin within normal institutional limits - AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal - Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal. - Subjects with ECOG performance status of 0 or 1. Exclusion Criteria: - Subjects who are pregnant or nursing at the time of diagnosis. - Subjects who are sexually active and not willing/able to use medically acceptable forms of contraception (hormonal or barrier method of birth control, abstinence) upon entering the study and for 60 days after injection of LUM015. - Subjects who have taken an investigational drug within 30 days of enrollment. - Subjects who have not recovered from adverse events due to other pharmaceutical or diagnostic agents. - Subjects with uncontrolled hypertension defined as persistent systolic blood pressure > 180 mm Hg, or diastolic blood pressure > 100 mm Hg; those subjects with known HTN should be under these values while under pharmaceutical therapy. - History of allergic reaction attributed to drugs containing polyethylene glycol (PEG). - History of allergic reaction to any oral or intravenous contrast agents. - Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements. - HIV-positive individuals on combination antiretroviral therapy are ineligible. - Any subject for whom the investigator feels participation is not in the best interest of the subject. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Lumicell, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology | Correlate the fluorescence levels in tumor tissue imaging to the dose of LUM015 injected. | 1 Day | |
Secondary | Number of patients with reported adverse events | Reported adverse events will be assessed and aggregated according to event type, relation to device or drug, and severity. | up to 5 weeks post surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03422432 -
Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases
|
N/A | |
Not yet recruiting |
NCT06295094 -
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
|
Phase 2 | |
Recruiting |
NCT05056389 -
Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)
|
Phase 1 | |
Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 | |
Recruiting |
NCT06367270 -
The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies
|
Phase 2 | |
Recruiting |
NCT05623787 -
Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms
|
N/A | |
Not yet recruiting |
NCT05095467 -
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT04083547 -
Circulating Tumour Cells in Patients With Peritoneal Metastases
|
||
Recruiting |
NCT06216561 -
Intraperitoneal LSTA1 in CRS-HIPEC
|
Phase 1 | |
Recruiting |
NCT05277766 -
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05318794 -
Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT05665257 -
Feasibility of Preoperative Inspiratory Muscle Training for Patients With Peritoneal Metastases
|
N/A | |
Terminated |
NCT05581719 -
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05379790 -
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
|
Phase 1 | |
Recruiting |
NCT05204173 -
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
|
Phase 2 | |
Recruiting |
NCT04956068 -
PIPAC for Peritoneal Metastases
|
Phase 1 | |
Recruiting |
NCT04861558 -
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
|
Phase 3 | |
Recruiting |
NCT05340569 -
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
|
N/A | |
Completed |
NCT03733184 -
Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases
|
||
Recruiting |
NCT06046963 -
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
|
Phase 2 |